Huiting Xu

No. 68, Zhongshan Rd
Wuxi, 214002, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

Journal: Nature medicine

Published: April 17, 2026

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

Journal: BMJ (Clinical research ed.)

Published: March 12, 2026

Chinese consensus on first-line precision therapy for advanced gastric cancer.

Chinese consensus on first-line precision therapy for advanced gastric cancer.

Journal: Innovation (Cambridge (Mass.))

Published: September 16, 2025

Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors.

Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors.

Journal: Experimental hematology & oncology

Published: July 24, 2025

A metal-free synthesis of phosphoramidates via I--catalyzed oxidative coupling of anilines/amines with H-phosphonates.

A metal-free synthesis of phosphoramidates via I--catalyzed oxidative coupling of anilines/amines with H-phosphonates.

Journal: Molecular diversity

Published: July 08, 2025

Biomacromolecule-mediated targeted protein degradation: an emerging strategy for cancer therapy.

Biomacromolecule-mediated targeted protein degradation: an emerging strategy for cancer therapy.

Journal: European journal of medicinal chemistry

Published: May 20, 2025

Machine learning-based predictive model for immune checkpoint inhibitors response in gastrointestinal cancers.

Machine learning-based predictive model for immune checkpoint inhibitors response in gastrointestinal cancers.

Journal: Frontiers in medicine

Published: May 19, 2025

TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study.

TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study.

Journal: Cancer cell

Published: April 29, 2025

Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.

Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.

Journal: British journal of cancer

Published: April 15, 2025

Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Journal: Nature medicine

Published: March 27, 2025

DA-MoE: Addressing depth-sensitivity in graph-level analysis through mixture of experts.

DA-MoE: Addressing depth-sensitivity in graph-level analysis through mixture of experts.

Journal: Neural networks : the official journal of the International Neural Network Society

Published: December 22, 2024

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.

Journal: Nature medicine

Published: October 18, 2024

Showing 1-12 of 36

Last Updated: 09/26/2026